EMA Authorised: Veyvondi (vonicog alfa) — Baxalta Innovations GmbH

View source ↗

Summary

The European Medicines Agency authorised Veyvondi (vonicog alfa) by Baxalta Innovations GmbH for the treatment of von Willebrand disease. This approval introduc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• Veyvondi (vonicog alfa)

Snippet

Status: Authorised. Therapeutic area: von Willebrand Diseases. MAH: Baxalta Innovations GmbH. Decision date: 18/12/2025